Recent Research on Epidemic Viruses

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 869

Special Issue Editor

Department of Cell Biology, Albert Einstein College of Medicine, New York, NY 10461, USA
Interests: cell–cell transmission of alphaviruses; interplay between cellular membrane trafficking proteins and viruses

Special Issue Information

Dear Colleagues,

Epidemic viruses cause an infectious disease that affects a large number of people within a community or population. This infectious disease qualifies as an epidemic when it spreads over multiple countries. Some of the most significant epidemics of the 21st century include those caused by emerging viruses such as SARS-associated coronavirus, Ebola virus, Zika virus, influenza A virus, and most recently SARS-CoV-2, which began as an epidemic before eventually and evolving into and being classified as a pandemic. Viral epidemics are increasing in infectivity and frequency. More than 200 human viruses have been discovered, and there is also a much larger number of animal viruses that can be potentially infectious to humans as well. It is essential to monitor potential epidemic virus infections in the human population and fill the different virological knowledge gaps. 

This Special Issue focuses on the most recent progress in epidemic viruses. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Genetic diversity and evolution of epidemic viruses;
  • Virus–cell interactions of epidemic viruses;
  • Cellular response to infection of epidemic viruses;
  • Vaccines and antiviral agents of epidemic viruses;
  • Pathogenesis and immunity of epidemic viruses.

Dr. Peiqi Yin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epidemic virus

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop